Mutant huntingtin represses CBP, but not p300, by binding and protein degradation

被引:35
作者
Cong, SY
Pepers, BA
Evert, BO
Rubinsztein, DC
Roos, RAC
van Ommen, GJB
Dorsman, JC
机构
[1] Leiden Univ, Ctr Med, CBG Ctr Human & Clin Genet, NL-2333 AL Leiden, Netherlands
[2] Leiden Univ, Ctr Med, Dept Neurol, Leiden, Netherlands
[3] China Med Univ, Affiliated Hosp 2, Dept Neurol, Shenyang, Peoples R China
[4] Univ Bonn, Dept Neurol, D-5300 Bonn, Germany
[5] Cambridge Inst Med Res, Dept Med Genet, Cambridge, England
[6] Ctr Med Syst Biol, Leiden, Netherlands
[7] Ctr Med Syst Biol, Amsterdam, Netherlands
[8] Ctr Med Syst Biol, Rotterdam, Netherlands
[9] Vrije Univ Amsterdam, Ctr Med, NL-1081 HV Amsterdam, Netherlands
关键词
D O I
10.1016/j.mcn.2005.05.003
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Huntington's disease can be used as a model to study neurodegenerative disorders caused by aggregation-prone proteins. It has been proposed that the entrapment of transcription factors in aggregates plays an important role in pathogenesis. We now report that the transcriptional activity of CBP is already repressed in the early time points by soluble mutant huntingtin, whereas the histone acetylase activity of CBP/p300 is gradually diminished over time. Mutant huntingtin bound much stronger to CBP than normal huntingtin, possibly contributing to repression. Especially at the later time points, CBP protein level was gradually reduced via the proteasome pathway. In sharp contrast, p300 was unaffected by mutant huntingtin. This selective degradation of CBP was absent in spinocerebellar ataxia 3. Thus, mutant huntingtin specifically affects CBP and not p300 both at the early and later time points, via multiple mechanisms. In addition to the reduction of CBP, also the altered ratio of these closely related histone acetyltransferases may affect chromatin structure and transcription and thus contribute to neurodegeneration. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:12 / 23
页数:12
相关论文
共 50 条
[41]   CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein [J].
Scolnick, DM ;
Chehab, NH ;
Stavridi, ES ;
Lien, MC ;
Caruso, L ;
Moran, E ;
Berger, SL ;
Halazonetis, TD .
CANCER RESEARCH, 1997, 57 (17) :3693-3696
[42]   Physical and functional interaction of SMADs and p300/CBP [J].
Pouponnot, C ;
Jayaraman, L ;
Massagué, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (36) :22865-22868
[43]   CBP/p300 are bimodal regulators of Wnt signaling [J].
Li, Jiong ;
Sutter, Chris ;
Parker, David S. ;
Blauwkamp, Timothy ;
Fang, Ming ;
Cadigan, Ken M. .
EMBO JOURNAL, 2007, 26 (09) :2284-2294
[44]   CBP/p300 acetyltransferase activity in hematologic malignancies [J].
Dutta, Ritika ;
Tiu, Bruce ;
Sakamoto, Kathleen M. .
MOLECULAR GENETICS AND METABOLISM, 2016, 119 (1-2) :37-43
[45]   Roles of the acetyltransferases CBP/p300 in breast cancer [J].
Muhmud, Iqbal ;
Tian, Guimei ;
Liao, Daiqing .
CANCER RESEARCH, 2017, 77
[46]   Conjunction dysfunction: CBP/p300 in human disease [J].
Giles, RH ;
Peters, DJM ;
Breuning, MH .
TRENDS IN GENETICS, 1998, 14 (05) :178-183
[47]   CBP/p300 in cell growth, transformation, and development [J].
Goodman, RH ;
Smolik, S .
GENES & DEVELOPMENT, 2000, 14 (13) :1553-1577
[48]   CBP/p300 and muscle differentiation: no HAT, no muscle [J].
Polesskaya, A ;
Naguibneva, I ;
Fritsch, L ;
Duquet, A ;
Ait-Si-Ali, S ;
Robin, R ;
Vervisch, A ;
Pritchard, LL ;
Cole, P ;
Harel-Bellan, A .
EMBO JOURNAL, 2001, 20 (23) :6816-6825
[49]   Targeting CBP and p300: Emerging Anticancer Agents [J].
Masci, Domiziana ;
Puxeddu, Michela ;
Silvestri, Romano ;
La Regina, Giuseppe .
MOLECULES, 2024, 29 (19)
[50]   The transcriptional coactivators p300 and CBP are histone acetyltransferases [J].
Ogryzko, VV ;
Schiltz, RL ;
Russanova, V ;
Howard, BH ;
Nakatani, Y .
CELL, 1996, 87 (05) :953-959